EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Analysis of TGF-β1 Levels in Bronchoalveolar Lavage Fluid among Lung Cancer, Suspected, and Non-Cancer Patients

Muhammad Khairul Afif, Herry Priyanto, Teuku Zulfikar

Jurnal Respirologi Indonesia · 31.07.2026 · 46 (3) · 141-147

DOI: 10.36497/jri.v46i3.1112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Jurnal Respirologi Indonesia, online erschienen am 31.07.2026. Verfasst von Muhammad Khairul Afif und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer remains the leading cause of cancer-related mortality worldwide and is often diagnosed at an advanced stage. TGF-β1 plays a pivotal role in carcinogenesis and may serve as a diagnostic biomarker. BALF represents a relevant medium for assessing biomarkers that reflect the tumor microenvironment. This study aimed to evaluate TGF-β1 levels in BALF and determine its diagnostic performance and optimal cut-off value for lung cancer.

Methods

This cross-sectional analytical study was conducted at Dr. Zainoel Abidin General Hospital, Banda Aceh, from April to June 2025, involving 64 patients (34 lung cancer patients, 9 suspected lung cancer patients, and 21 non-cancer patients). BALF samples were obtained via bronchoscopy, and TGF-β1 levels were measured using ELISA. Statistical analyses included the Mann-Whitney U test and ROC curve analysis.

Results

Median TGF-β1 levels were 66.24 pg/mL in the non-cancer group, 136.93 pg/mL in the suspected lung cancer group, and 200.25 pg/mL in the lung cancer group. The combined suspected/lung cancer group showed significantly higher levels than the non-cancer group (P=0.025). ROC analysis yielded an area under the curve (AUC) of 0.674 (95% CI=0.529-0.819; P=0.025). The optimal cut-off value was 105.63 pg/mL, with a sensitivity of 67.44%, specificity of 61.90%, positive predictive value of 78.38%, and negative predictive value of 48.15%.

Conclusion

TGF-β1 levels in BALF demonstrate potential as a diagnostic biomarker for lung cancer with moderate performance. It may serve as a supportive “rule-in” test to strengthen clinical suspicion but is insufficient as a stand-alone diagnostic tool. Combining TGF-β1 with other biomarkers in a multiparametric diagnostic panel is recommended to improve diagnostic accuracy.

Zitieren

APA

Afif, M. K., Priyanto, H., & Zulfikar, T. (2026). Analysis of TGF-β1 Levels in Bronchoalveolar Lavage Fluid among Lung Cancer, Suspected, and Non-Cancer Patients. Jurnal Respirologi Indonesia, 46(3), 141-147. https://doi.org/10.36497/jri.v46i3.1112

Vancouver

Afif MK, Priyanto H, Zulfikar T. Analysis of TGF-β1 Levels in Bronchoalveolar Lavage Fluid among Lung Cancer, Suspected, and Non-Cancer Patients. Jurnal Respirologi Indonesia. 2026;46(3):141-147. doi:10.36497/jri.v46i3.1112

BibTeX
@article{Afif2026,
  author = {Afif, Muhammad Khairul and Priyanto, Herry and Zulfikar, Teuku},
  title = {Analysis of TGF-β1 Levels in Bronchoalveolar Lavage Fluid among Lung Cancer, Suspected, and Non-Cancer Patients},
  journal = {Jurnal Respirologi Indonesia},
  year = {2026},
  volume = {46},
  number = {3},
  pages = {141--147},
  doi = {10.36497/jri.v46i3.1112}
}
Kostenlos starten →